Medbroadcast  Powered by MediResource
 Search

Go
 Browse alphabetically
ABCDEFGHIJKLMN
OPQRSTUVWXYZ
HEALTH TOPICS
Family & Child Health
Men's Health
Women's Health
Seniors' Health
Addiction
Allergy
Ankylosing Spondylitis
Arthritis (Rheumatoid)
Asthma
Atrial Fibrillation
Baby Health
Back Health
Bedwetting
Bladder (Overactive)
Brain Health
Cancer
Childhood Vaccinations
Cholesterol
Crohn's & Colitis
Cold and Flu
COPD NEW!
Cosmetic Procedures
Depression NEW!
Diabetes
Digestive Health
Ear Health
Eating Disorders
Eye Health
Flu (Seasonal)
Fertility
Fitness
Healthy Skin
Heart
High Blood Pressure
HPV
Hyperhidrosis
Incontinence
Infection
Kidney Health
Lung Health
Medications and your Health
Menopause
Mental Health
Multiple Sclerosis NEW!
Natural and Complementary Therapy
Nutrition
Obesity
Oral Care
Osteoarthritis of the Knee NEW!
Pain
Pregnancy
Psoriasis
Psoriatic Arthritis (PsA)
Seasonal Health
Sexual Health
Sleep Health
Stroke Risk Reduction
Smoking
Weight Management
Workplace Health
Yeast Infection
All health channels

STAY CONNECTED
RESOURCES
Ask an Expert
Clinical Trials
Find a Specialist
Health features
News
Tools


Condition Info Drug Info Tests and Procedures Natural Products Ask an Expert Support Groups Clinical Trials
Home Bookmark Page Send to a Friend Sante Chez Nous Subscribe
Drug Info > Z > Zometa
Please enter the drug name or
DIN (Drug Identification Number)


GoGO

Search by first letter

ABCDEFGHIJKLMNOPQRSTUVWXYZ

Brand Name

Zometa

Common Name
zoledronic acid for injection


In this drug factsheet:



DIN (Drug Identification Number)

02248296 ZOMETA 4MG/5ML CONCENTRATE FOR INJECTION

How does this medication work? What will it do for me?

Zoledronic acid belongs to the family of medications known as bisphosphonates. It is used to treat hypercalcemia (high blood calcium) for people who have cancer. Zoledronic acid is also used to prevent or delay complications (e.g., bone fractures or bone pain requiring surgery or radiotherapy) due to cancer that has spread to bones (bone metastases) from different types of tumours and multiple myeloma (cancer of the bone marrow).

This medication works by slowing the rate of bone change and may prevent bone breakdown and uncontrolled bone growth caused by cancer that has spread to the bone.

Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. As well, some forms of this medication may not be used for all of the conditions discussed here. If you have not discussed this with your doctor or are not sure why you are being given this medication, speak to your doctor. Do not stop receiving this medication without consulting your doctor.

How should I use this medication?

The dosage of this medication depends on the condition that is being treated.

For tumour-induced hypercalcemia (high calcium levels in the blood), the recommended starting dose of zoledronic acid for hypercalcemia is 4 mg given as a single intravenous injection (into the vein) over no less than 15 minutes. This dose may be repeated after at least 1 week for people who do not respond completely to this dose or whose calcium level does not remain normal.

For bone metastases and multiple myeloma, the recommended dose of zoledronic acid for bone metastases is 4 mg given as a single intravenous injection (into the vein) over no less than 15 minutes every 3 to 4 weeks. For people receiving chemotherapy, zoledronic acid may be given either before or after treatment.

It is important to take a calcium supplement of 500 mg by mouth and a multivitamin containing at least 400 IU of vitamin D daily, unless high blood calcium levels develop. If this occurs, calcium and vitamin D supplements should be discontinued as advised by your doctor.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are receiving the medication without consulting your doctor.

It is important this medication be given exactly as recommended by your doctor. If you miss an appointment to receive zoledronic acid, contact your doctor as soon as possible to reschedule your appointment.

This medication is stored at room temperature. After mixing, it is stored in the refrigerator. Keep this medication out of the sight and reach of children and pets.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.





What form(s) does this medication come in?

Each 5 mL vial of concentrated sterile liquid for intravenous (IV) injection contains 4 mg of zoledronic acid. Nonmedicinal ingredients: mannitol, sodium citrate, and water for injection.

Who should NOT take this medication?

Zoledronic acid should not be given to anyone who:

  • is allergic to zoledronic acid, other bisphosphonates (e.g., alendronate, etidronate, risedronate), or to any of the ingredients of this medication
  • is breast-feeding
  • is pregnant


 

Advertisement


Did you find what you were looking for on our website? Please let us know.


 Search for information related to
GO
ABCDEFGHIJKLMNOPQRSTUVWXYZ
 

Hot Topics - Bedwetting, Depression, Flu (Seasonal), Healthy Skin, Incontinence, Multiple Sclerosis, Psoriasis, Stroke Risk Reduction

Condition and disease information is written and reviewed by the MedBroadcast Clinical Team.


The contents of this site are for informational purposes only and are meant to be discussed with your physician or other qualified health care professional before being acted on. Never disregard any advice given to you by your doctor or other qualified health care professional. Always seek the advice of a physician or other licensed health care professional regarding any questions you have about your medical condition(s) and treatment(s). This site is not a substitute for medical advice.
© 1996 - 2014 MediResource Inc. - MediResource reaches millions of Canadians each year.